logo-loader

Erectile dysfunction drugmaker Mangoceuticals fails to maintain IPO price

Published: 13:55 23 Mar 2023 EDT

IPO on fire graphic

Mangoceuticals shares have dropped nearly 10% Thursday, the second straight day of big losses for the men’s wellness company after it went public on Tuesday. 

Shares of the Dallas-based company debuted at $4.20 Tuesday morning but had dropped to $3.05 by Wednesday’s closing bell. 

By Thursday afternoon, shares were down another 9.2% to $2.77. 

Mangoceuticals caught investors' attention for developing a quick-dissolving tablet for erectile dysfunction that contains the same active ingredient found in the drug Cialis.

A selling point was Mangoceuticals’ plan to market the product directly to consumers using a telehealth platform on its website. 

The company underwent a $5 million IPO, pricing 1.25 million shares at $4 per share. 

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 48 minutes ago